In the latest close session, Hims & Hers Health, Inc. (HIMS) was down 1.73% at $32.96. The stock's performance was behind the S&P 500's daily loss of 1.44%. On the other hand, the Dow registered a ...

Learn more Leerink maintained a 'Market Perform' rating and a $25 price target, implying a 10% downside from current levels.

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $27.71, moving -4.38% from the previous trading session. This change lagged the S&P 500's 1.62% loss on the day. Meanwhile, the ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, saw its stock surge 8% on Friday, May 30th, following the announcement of a 4% workforce reduction. This adjustment comes as the company adapts ...

HIMS is expanding into hormone health and diagnostics to deepen subscriber value and care personalization. GDRX is growing pharma-manufacturer services and retail integrations to enhance transparency ...

Shares of Hims & Hers Health (HIMS) surged more than 45% on Monday morning, a move that is likely to ripple across a broad range of exchange traded funds that hold the telehealth provider. The rally ...

Hims & Hers Health, Inc. (HIMS Quick Quote HIMS - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might ...